We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Btg Plc | LSE:BTG | London | Ordinary Share | GB0001001592 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 840.00 | 839.00 | 840.00 | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMBTG
RNS Number : 5273X
BTG PLC
27 November 2017
BTG plc: Appointment of Non-executive Director
London, UK, 27 November 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces the appointment of Gregory Barrett as a non-executive director of the Board.
Greg has a broad range of commercial experience in the US medtech industry, with a focus on interventional medicine therapies. He is currently a non-executive director of Cutera Inc and was previously President and Chief Executive Officer of DFINE Inc, Barrx Medical Inc, and ACMI Corporation. Prior roles include leading a minimally invasive surgery division of Boston Scientific, both in US and in emerging markets. Greg has also held a series of senior sales and marketing roles at a number of companies including Baxter Healthcare and C.R. Bard.
Garry Watts, BTG's Chairman, commented: "Greg brings a strong track record to BTG, with significant US commercial and international medtech experience, which will be of great benefit to us as we continue to implement our growth plans."
There are no further details to be disclosed in relation to paragraph 9.6.13R of the Financial Conduct Authority Listing Rules.
For further information contact:
BTG
Andy Burrows, VP Corporate & Investor Relations
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530 605
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
Chris Sampson, Corporate Communications Director
+44 (0)20 7575 1595; Mobile: +44 (0)7773 251 178
FTI Consulting
Ben Atwell/Simon Conway
+44 (0)20 3727 1000
About BTG
BTG is a global specialist healthcare company bringing to market innovative products in specialist areas of medicine to better serve doctors and their patients. We have a portfolio of Interventional Medicine products to advance the treatment of cancer, severe emphysema, severe blood clots and varicose veins, and Specialty Pharmaceuticals that help patients overexposed to certain medications or toxins. Inspired by patient and physician needs, BTG is investing to expand its portfolio to address some of today's most complex healthcare challenges. To learn more about BTG, please visit: btgplc.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOALLFSDLVLRFID
(END) Dow Jones Newswires
November 27, 2017 02:00 ET (07:00 GMT)
1 Year Btg Chart |
1 Month Btg Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions